Expression of p63, TTF–1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis / Küçük Hücreli Dışı Akciğer Karsinomunda p63, TTF-1 ve Maspin Ekspresyonu - Prognoz ve Ayırıcı Tanı Üzerine Etkileri
Objective: Lung cancer is still the leading cause of cancer mortality. Antiapoptotic genes and protease inhibitors play an important role in the development of lung cancer.
Material and Method: p63, TTF-1 and maspin expression and their role in the differential diagnosis, overall survival, progression-free survival and other clinicopathological characteristics of the patients were investigated in 80 surgically-resected non-small cell lung carcinomas.
Results: The maximal tumor diameter range was 1.5-11 cm (mean: 4.06±1.8 cm). Forty-five (56.3%) tumors were adenocarcinoma, 23 (28.8%) squamous cell carcinoma, four (5%) large cell carcinoma, six (7.5%) large cell neuroendocrine carcinoma, one (1.2%) sarcomatoid carcinoma while one was (1.2%) both adenocarcinoma and squamous cell carcinoma. The patients with advanced TNM stage and a tumor diameter more than 3 cm had markedly poor survival. Immunohistochemically, p63 staining was present in 87.5% of squamous cell carcinomas, 4.3% of adenocarcinomas, 25% of large cell carcinomas, and 16.7% of large cell neuroendocrine carcinomas. Similarly, maspin was positive in 66.7% of squamous cell carcinomas and 17.4% of adenocarcinomas. The TTF-1 staining rate was higher in adenocarcinomas (84.8%). There was no immunoreactivity in squamous cell carcinomas (p<0.001). We found that p63 and TTF-1 had no significant effect on survival in either tumor group (p>0.05) while maspin has a negative prognostic effect in adenocarcinoma (p=0.048).
Conclusion: This study suggests that p63 and TTF-1 are reliable markers in non-small cell lung carcinoma and can be used in differential diagnosis. Maspin has been identified as a prognostic marker in adenocarcinoma. However, more studies are required to elucidate the significance of maspin.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Olak J Colson Y. Gender differences in lung cancer: Have we really come a long way baby? Thorac Cardiovasc Surg. 2004;128:346-51.
2. William D. Travis Elisabeth Brambilla H. Konrad Müller- Hermelink Curtis C. Harris. Pathology and genetics of tumors of the lung pleura thymus and heart. Kleihues P Sobin LH editors. Lyon: IARC;2004
3. Massion PP Taflan PM Jamshedur Rahman SM Yildiz P Shyr Y Edgerton ME Westfall MD Roberts JR Pietenpol JA Carbone DP Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63:7113-21.
4. Wang BY Gil J Kaufman D Gan L Kohtz DS Burstein DE. P63 in pulmonary epithelium pulmonary squamous neoplasms and other pulmonary tumors. Hum Pathol. 2002;33:921-6.
5. Afify AM al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol. 2002;46:675-8.
6. Di Loreto C Di Lauro V Puglisi F Damante G Fabbro D Beltrami CA. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol. 1997;50:30-2.
7. Smith SL Watson SG Ratschiller D Gugger M Betticher DC Heighway J. Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene. 2003;22:8677-87.
8. Katakura H Takenaka K Nakagawa M Sonobe M Adachi M Ito S Wada H Tanaka F. Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC). Maspin in NSCLC. Lung Cancer. 2006;51:323-8.
9. Nakashima M Ohike N Nagasaki K Adachi M Morohoshi T. Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2004;130:475-9.
10. Au NH Cheang M Huntsman DG Yorida E Coldman A Elliott WM Bebb G Flint J English J Gilks CB Grimes HL. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: A tissue microarray study of 284 cases and 18 markers. J Pathol. 2004;204:101-9.
11. Berghmans T Mascaux C Martin B Ninane V Sculier JP. Prognostic role of thyroid transcription factor-1 in stage III nonsmall cell lung cancer. Lung Cancer. 2006;52:219-24.
12. Goksel T Akkoclu A. Pattern of lung cancer in Turkey 1994-1998. Respiration. 2002;69:207-10.
13. Hirsch FR Franklin WA Gazdar AF Bunn PA Jr. Early detection of lung cancer: Clinical perspectives of recent advances in biology and radiology. Clin Cancer Res. 2001;7:5-22.
14. Brundage MD Davies D Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest. 2002;122:1037-57.
15. Ou SH Zell JA Ziogas A Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: A populationbased analysis of 19702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007;110:1532-41.
16. Irwin MS Kaelin WG Jr. Role of the newer p53 family proteins in malignancy. Apoptosis. 2001;6:17-29.
17. Yang A Kaghad M Wang Y Gillett E Fleming MD Dötsch V Andrews NC Caput D McKeon F. p63 a p53 homolog at 3q27-29 encodes multiple products with transactivating death-inducing and dominant-negative activities. Mol Cell. 1998;2:305-16.
18. Brunner HG Hamel BC Bokhoven Hv H. P63 gene mutations and human developmental syndromes. Am J Med Genet. 2002;112:284-90.
19. Au NH Gown AM Cheang M Huntsman D Yorida E Elliott WM Flint J English J Gilks CB Grimes HL. P63 expression in lung carcinoma: A tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12:240-7.
20. Kaufmann O Fietze E Mengs J Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823-30.
21. Pelosi G Pasini F Olsen Stenholm C Pastorino U Maisonneuve P Sonzogni A Maffini F Pruneri G Fraggetta F Cavallon A Roz E Iannucci A Bresaola E Viale G. p63 immunoreactivity in lung cancer: Yet another player in the development of squamous cell carcinomas? J Pathol. 2002;198:100-9.
22. Wu M Wang B Gil J Sabo E Miller L Gan L Burstein DE. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Diagn Cytopathol. 2003;119:696-702.
23. Iwata T Uramoto H Sugio K Fujino Y Oyama T Nakata S Ono K Morita M Yasumoto K. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer. 2005;50:67-73.
24. Shtilbans V Szporn AH Wu M Burstein DE. p63 immunostaining in destained bronchoscopic cytological specimens. Diagn Cytopathol. 2005;32:198-203.
25. Wu M Szporn AH Zhang D Wasserman P Gan L Miller L Burstein DE. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol. 2005;33:223-7.
26. Camilo R Capelozzi VL Siqueira SA Del Carlo Bernardi F. Expression of p63 keratin 5/6 keratin 7 and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37:542-6.
27. Kargi A Gurel D Tuna B. The diagnostic value of TTF-1 CK 5/6 and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007;15:415-20.
28. Koh J Go H Kim MY Jeon YK Chung JH Chung DH. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. Histopathology. 2014;65:868-78.
29. Xu XY Yang GY Yang JH Li J. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: Utility of an immunohistochemical panel containing CK5/6 CK34betaE12 p63 CK7 and TTF-1. Pathol Res Pract. 2014;210:680-5.
30. Shah L Walter KL Borczuk AC Kawut SM Sonett JR Gorenstein LA Ginsburg ME Steinglass KM Powell CA. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer. 2004;101:1632-8.
31. Pu RT Pang Y Michael CW. Utility of WT-1 p63 MOC31 mesothelin and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma squamous cell carcinoma and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36:20-5.
32. Brunnstrom H Johansson L Jirstrom K Jonsson M Jonsson P Planck M. Immunohistochemistry in the differential diagnostics of primary lung cancer: An investigation within the Southern Swedish Lung Cancer Study. Am J Clin Pathol. 2013;140:37-46.
33. Hiroshima K Iyoda A Shida T Shibuya K Iizasa T Kishi H Tanizawa T Fujisawa T Nakatani Y. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: A morphological immunohistochemical and molecular analysis. Mod Pathol. 2006;19:1358-68.
34. Z hang H Liu J Cagle PT Allen TC Laga AC Zander DS. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: An immunohistochemical approach. Mod Pathol. 2005;18:111-8.
35. Kalhor N Zander DS Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol. 2006;19:1117-23.
36. Tan D Li Q Deeb G Ramnath N Slocum HK Brooks J Cheney R Wiseman S Anderson T Loewen G. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34:597-604.
37. R eynolds PR Mucenski ML Whitsett JA. Thyroid transcription factor (TTF) -1 regulates the expression of midkine (MK) during lung morphogenesis. Dev Dyn. 2003;227:227-37.
38. M yong NH. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: Its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins. J Korean Med Sci. 2003;18:494-500.
39. Jerome Marson V Mazieres J Groussard O Garcia O Berjaud J Dahan M Carles P Daste G. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: Correlation with histological type and grade. Histopathology. 2004;45:125-34.
40. Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol. 2004;8:259-67.
41. Stenhouse G Fyfe N King G Chapman A Kerr KM. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol. 2004;57:383-7.
42. Chang YL Lee YC Liao WY Wu CT. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung cancer. 2004;44:149-57.
43. Srodon M Westra WH. Immunohistochemical staining for thyroid transcription factor-1: A helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol. 2002;33:642-5.
44. Yatabe Y Mitsudomi T Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26:767-73.
45. Sood AK Fletcher MS Gruman LM Coffin JE Jabbari S Khalkhali-Ellis Z Arbour N Seftor EA Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002; 8:2924-32.
46. Bailey CM Khalkhali-Ellis Z Seftor EA Hendrix MJ. Biological functions of maspin. J Cell Physiol. 2006; 209:617-24.
47. Bailey CM Khalkhali-Ellis Z Kondo S Margaryan NV Seftor RE Wheaton WW Amir S Pins MR Schutte BC Hendrix MJ. Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: Identification of a novel serpin partnership. J Biol Chem. 2005; 280:34210-7.
48. Nakagawa M Katakura H Adachi M Takenaka K Yanagihara K Otake Y Wada H Tanaka F. Maspin expression and its clinical significance in non-small cell lung cancer. Ann Surg Oncol. 2006;13:1517-23.
49. Hirai K Koizumi K Haraguchi S Hirata T Mikami I Fukushima M Yamagishi S Kawashima T Okada D Shimizu K Kawamoto M. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg. 2005;79:248-53.
50. Woenckhaus M Bubendorf L Dalquen P Foerster J Blaszyk H Mirlacher M Soler M Dietmaier W Sauter G Hartmann A Wild PJ. Nuclear and cytoplasmic Maspin expression in primary nonsmall cell lung cancer. J Clin Pathol. 2007;60:483-6.
51. Bircan A Bircan S Kapucuoglu N Songur N Ozturk O Akkaya A. Maspin VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters. Pathol Oncol Res. 2010;16:553-61.
52. Wu S Yu L Cheng Z Song W Zhou L Tao Y. Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry. J Huazhong Univ Sci Technolog Med Sci. 2012;32:346-52.
53. Lonardo F Li X Siddiq F Singh R Al-Abbadi M Pass HI Sheng S. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer. 2006;51:31-9.
54. Kim S Han J Kim J Park C. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res. 2004;64:6900-5.
55. Berardi R Santinelli A Onofri A Brunelli A Pierantoni C Pisa E Pagliacci A Stramazzotti D Zuccatosta L Mazzanti P Sabbatini A Gasparini S Bearzi I Cascinu S. Maspin expression is a favorable prognostic factor in non-small cell lung cancer. Anal Quant Cytol Histol. 2012;34:72-8.
56. Takagi Y Matsuoka Y Shiomi T Nosaka K Takeda C Haruki T Araki K Taniguchi Y Nakamura H Umekita Y. Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring <3 cm. Histopathology. 2015; 66:732-9.
57. Takanami I Abiko T Koizumi S. Expression of maspin in nonsmall- cell lung cancer: Correlation with clinical features. Clin Lung Cancer. 2008;9:361-6.
58. Choy B Findeis-Hosey JJ Li F McMahon LA Yang Q Xu H. High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung. J Clin Exp Pathol. 2013;6:2542-7.